Glucocorticoid-induced osteoporosis

Glucocorticoid-induced osteoporosis is a form of secondary, iatrogenic metabolic bone disease affecting the skeletal system in patients undergoing systemic glucocorticoid therapy This imbalance causes rapid deterioration of trabecular and cortical microarchitecture, resulting in reduced bone mineral density, compromised bone quality, and a heightened susceptibility to fragility fractures—predominantly in the vertebrae and femoral neck—even at higher bone density levels than observed in primary o...

Glucocorticoid-induced osteoporosis is a form of secondary, iatrogenic metabolic bone disease affecting the skeletal system in patients undergoing systemic glucocorticoid therapy Pathophysiologically, glucocorticoids impair skeletal remodeling by suppressing osteoblast differentiation and promoting osteoblast and osteocyte apoptosis, which markedly diminishes bone formation while transiently stimulating osteoclast-mediated bone resorption

Pathophysiologically, glucocorticoids impair skeletal remodeling by suppressing osteoblast differentiation and promoting osteoblast and osteocyte apoptosis, which markedly diminishes bone formation while transiently stimulating osteoclast-mediated bone resorption

This imbalance causes rapid deterioration of trabecular and cortical microarchitecture, resulting in reduced bone mineral density, compromised bone quality, and a heightened susceptibility to fragility fractures—predominantly in the vertebrae and femoral neck—even at higher bone density levels than observed in primary osteoporosis

This imbalance causes rapid deterioration of trabecular and cortical microarchitecture, resulting in reduced bone mineral density, compromised bone quality, and a heightened susceptibility to fragility fractures—predominantly in the vertebrae and femoral neck—even at higher bone density levels than observed in primary osteoporosis